BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18036687)

  • 41. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
    Sato T; Kokuba Y; Koizumi W; Hayakawa K; Okayasu I; Watanabe M
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1442-7. PubMed ID: 17855009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integration of novel agents into combined-modality treatment for rectal cancer patients.
    Rödel C; Sauer R
    Strahlenther Onkol; 2007 May; 183(5):227-35. PubMed ID: 17497093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer.
    Clifford R; Govindarajah N; Parsons JL; Gollins S; West NP; Vimalachandran D
    Br J Surg; 2018 Nov; 105(12):1553-1572. PubMed ID: 30311641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. UGT1A1 genotype-guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN-38 concentration.
    Jiang PC; Wang SW; Li C; Fan J; Zhu J
    Int J Cancer; 2024 Apr; 154(8):1484-1491. PubMed ID: 38158593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Capecitabine in the treatment of rectal cancer.
    Beets GL; Beets-Tan RG
    Lancet Oncol; 2012 Jun; 13(6):560-1. PubMed ID: 22652229
    [No Abstract]   [Full Text] [Related]  

  • 48. Missing evidence for the adequacy of a 1-cm distal margin in resected rectal cancer.
    Smidt ML; Wegdam JA; Bremers AJ; Bleichrodt RP
    Ann Surg Oncol; 2003 Aug; 10(7):823-4. PubMed ID: 12900376
    [No Abstract]   [Full Text] [Related]  

  • 49. Current status of radiosensitizing agents for the management of rectal cancer.
    Illum H
    Crit Rev Oncog; 2012; 17(4):345-59. PubMed ID: 23176042
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Irinotecan and radiosensitization in rectal cancer.
    Illum H
    Anticancer Drugs; 2011 Apr; 22(4):324-9. PubMed ID: 21160419
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow-up of a paradigm-changing study: the paradigm still holds.
    Mamon HJ
    J Clin Oncol; 2012 Jun; 30(16):1901-3. PubMed ID: 22529256
    [No Abstract]   [Full Text] [Related]  

  • 52. Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
    Zhang J; Huang M; Cai Y; Wang L; Xiao J; Lan P; Hu H; Wu X; Ling J; Peng J; Chen D; Kang L; Zhang Y; Ren D; Wang H; Chen S; Lin F; Zheng J; Zhou Z; Wang J; Deng Y
    Clin Colorectal Cancer; 2019 Dec; 18(4):238-244. PubMed ID: 31378655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial.
    Abe S; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Yokoyama Y; Matsuzaki H; Nagai Y; Yoshioka Y; Shinagawa T; Sonoda H; Yamamoto Y; Oba K; Ishihara S
    BMC Cancer; 2023 May; 23(1):450. PubMed ID: 37198556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by
    Zhu J; Liu A; Sun X; Liu L; Zhu Y; Zhang T; Jia J; Tan S; Wu J; Wang X; Zhou J; Yang J; Zhang C; Zhang H; Zhao Y; Cai G; Zhang W; Xia F; Wan J; Zhang H; Shen L; Cai S; Zhang Z
    J Clin Oncol; 2020 Dec; 38(36):4231-4239. PubMed ID: 33119477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype.
    Guan Y; Shen Y; Xu Y; Li C; Wang J; Gu W; Lian P; Huang D; Cai S; Zhang Z; Zhu J
    Therap Adv Gastroenterol; 2019; 12():1756284819852293. PubMed ID: 31217818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.
    Schiffmann L; Wedermann N; Gock M; Prall F; Klautke G; Fietkau R; Rau B; Klar E
    BMC Surg; 2013 Sep; 13():43. PubMed ID: 24073705
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis.
    Schiffmann L; Klautke G; Wedermann N; Gock M; Prall F; Fietkau R; Rau B; Klar E
    BMC Cancer; 2013 Aug; 13():388. PubMed ID: 23947828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
    Gollins SW; Myint S; Susnerwala S; Haylock B; Wise M; Topham C; Samuel L; Swindell R; Morris J; Mason L; Levine E
    Br J Cancer; 2009 Sep; 101(6):924-34. PubMed ID: 19690550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
    Klautke G; Küchenmeister U; Foitzik T; Ludwig K; Semrau S; Prall F; Klar E; Fietkau R
    Radiother Oncol; 2007 Dec; 85(3):379-84. PubMed ID: 18036687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
    Hofheinz RD; von Gerstenberg-Helldorf B; Wenz F; Gnad U; Kraus-Tiefenbacher U; Müldner A; Hehlmann R; Post S; Hochhaus A; Willeke F
    J Clin Oncol; 2005 Mar; 23(7):1350-7. PubMed ID: 15684318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.